Pharmacokinetics of Dexamethasone when Administered with Fosaprepitant for Chemotherapy-Induced Nausea and Vomiting and Differences in Dose-Dependent Antiemetic Effects

BACKGROUND: Fosaprepitant, an NK(1) receptor antagonist, inhibits and induces cytochrome P450 3A4 (CYP3A4) as its substrate. Contrarily dexamethasone is metabolized by CYP3A4. Therefore, in combination therapy wherein both agents interact with each other, it is recommended that the dexamethasone dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimamoto, Fukutaro, Goto, Masahiro, Terazawa, Tetsuji, Asaishi, Ken, Miyamoto, Takahiro, Higuchi, Kazuhide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286666/
https://www.ncbi.nlm.nih.gov/pubmed/33773552
http://dx.doi.org/10.31557/APJCP.2021.22.3.871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286666/
https://www.ncbi.nlm.nih.gov/pubmed/33773552
http://dx.doi.org/10.31557/APJCP.2021.22.3.871

Ejemplares similares